Merck (MRK) Reports Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma

February 19, 2019 4:59 PM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles